Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07148713 · ClinicalTrials.gov registry record · NA
Pilot of Continuous Glucose Monitor-Augmented Food Is Medicine
A NA study of Type 2 Diabetes and Nutrition, sponsored by University of North Carolina, Chapel Hill.
- Recruiting
- Registry status
- NA
- Development phase
- 60
- Enrollment target
- 1
- Study location
NCT07148713 is a NA study of Type 2 Diabetes and Nutrition that is actively recruiting participants, run by University of North Carolina, Chapel Hill. The registered enrollment target is 60 participants, below the 1,102-participant average among 288 other Type 2 Diabetes trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state.
The verdict
NCT07148713, a NA study of Type 2 Diabetes and Nutrition, is actively recruiting participants, sponsored by University of North Carolina, Chapel Hill.
- RECRUITING
- Registry status
- NA
- Development phase
- 60 participants
- Enrollment target
- 1
- Study location
Study Summary
This study is designed to test the feasibility and preliminary efficacy of a continuous glucose monitor (CGM)-augmented food is medicine (FIM) intervention for adults with type 2 diabetes and nutrition or food insecurity. This study will learn if a FIM intervention ("intervention") that includes access to real-time CGM and nutrition counseling can increase engagement, improve glycemic management, and support healthy eating in this population, compared to the FIM intervention alone ("comparator"). At the study baseline, participants will be randomized to either the intervention or the comparator arm for 16 weeks. The intervention will occur during the first 12 weeks (phase 1: intervention phase) and will be compared to a standard FIM approach without CGM or counseling. Phase 2 (extension phase) will last 4 weeks and will consist of all participants in the intervention and comparator arm receiving both FIM and CGM for self-directed use. The study will also explore participant experiences through a series of semi-structured interviews with a subset of randomly selected participants to identify opportunities for scaling the intervention to a broader population.
Conditions Studied
Interventions
- BEHAVIORAL CGM-Augmented FIM
- BEHAVIORAL FIM only
Study Locations (1)
North Carolina
- University of North Carolina at Chapel Hill - Chapel Hill
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2025-09-19 |
| Est. Completion | 2026-06 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07148713
The ClinicalTrials.gov registry entry for NCT07148713 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,102-participant average among 288 other Type 2 Diabetes trials with a reported enrollment target (95% lower). The listed sponsor is University of North Carolina, Chapel Hill, which has 1,109 total studies on file at ClinicalTrials.gov.
The record links to 7 conditions, with Type 2 Diabetes appearing as the primary indexed condition, and to 2 interventions - of which CGM-Augmented FIM is the first listed.
NCT07148713 reports 1 study location spanning 1 distinct geographic area - top geographies include North Carolina.
Frequently Asked Questions
What is clinical trial NCT07148713 about?
NCT07148713 is a clinical study titled "Pilot of Continuous Glucose Monitor-Augmented Food Is Medicine". This study is designed to test the feasibility and preliminary efficacy of a continuous glucose monitor (CGM)-augmented food is medicine (FIM) intervention for adults with type 2 diabetes and nutrition or food insecurity. This study will learn if a FIM intervention ("intervention") that includes acc...
What is the current status of trial NCT07148713?
This trial is currently recruiting. It is a NA study. The enrollment target is 60 participants. The study started on 2025-09-19. Estimated completion is 2026-06.
What conditions does trial NCT07148713 study?
This clinical trial studies the following conditions: Type 2 Diabetes, Nutrition, Diabetes Type 2, T2DM (Type 2 Diabetes Mellitus), T2DM.
What interventions are being tested in trial NCT07148713?
The interventions under investigation include: CGM-Augmented FIM (BEHAVIORAL), FIM only (BEHAVIORAL).
Who is sponsoring clinical trial NCT07148713?
This trial is sponsored by University of North Carolina, Chapel Hill, which has 1,109 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07148713 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Type 2 Diabetes
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Enhancing Telemedicine for T2D
RECRUITING · NA
-
Sleep and Glycemic Control in Type 2 Diabetes Adolescents
RECRUITING · NA
-
Enhancing Preventative Health Behaviors Among Emergency Department Hyperglycemic Patients
RECRUITING · NA
-
Ultrasound Effects on Glycemic Control in T2DM
RECRUITING · NA
-
A Randomized Double-Blinded and Placebo-Controlled Trial to Assess the Efficacy of Biophoton Therapy to Treat Type 2 Diabetes
RECRUITING · NA
-
High Fructose Diet, the Gut Microbiome, and Metabolic Health
RECRUITING · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.